HIGHLIGHTS
- who: Danli Kong and colleagues from the Department of Epidemiology and Medical Statistics, School of Public Health, Guangdong Medical University, Dongguan, China have published the research: ATL I, Acts as a SIRT6 Activator to Alleviate Hepatic Steatosis in Mice via Suppression of NLRP3 Inflammasome Formation, in the Journal: Pharmaceuticals 2022, 15, x FOR PEER REVIEW of /2022/
- what: The authors aim to investigate the underlying mechanisms and pharmacological interventions of SIRT6 on hepatic steatosis treatment. The authors first explored the underlying mechanism by which ATL I regulates hepatic inflammation. In the present study, the results . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.